Verdict: Overreaction

Key finding: Q3 revenue was a record $99.3M (+39% YoY, +41% QoQ) with a GAAP profit, but the same release halved full-year adjusted EBITDA guidance ($80-100M to "more than $40M") and kept a revenue guide that needs Q4 sales up 37-52% sequentially, with management flagging a "reasonable" chance of landing modestly below it. The +20.4% gap was 85% erased within three sessions.

Scorecard

Ticker Rev last Q ($M) Rev YoY last Q Rev YoY prior Q Gross margin (last Q, trend) Op margin EPS last Q vs yr ago P/S Mkt cap 1-mo price %
HROW 99.3 +38.6% +10.9% 75.4% (up from 71.3%) +11.6% $0.25 vs $0.03 3.4x $1.04B -2.8%
TARS 194.6 +63.9% +69.4% 92.9% (flat ~93%) -340.3% (incl. a $630.6M other-expense line) -$14.40 vs -$0.30 4.7x $3.21B +3.3%
BLCO 1,375.0 +7.3% +8.7% 60.5% (up from 59.1%) +11.3% $0.09 vs -$0.08 1.4x $7.48B +31.5%
OCUL 12.9 -11.5% +0.1% 88.7% (up from 85.1%) — -$0.42 vs -$0.38 23.3x $1.18B -16.9%

HROW is the middle of the pack: its growth (+38.6%) trails Tarsus (+63.9%), but it is one of only two profitable names (op margin +11.6%) and trades at a lower P/S than Tarsus (3.4x vs 4.7x). HROW is the only one whose growth re-accelerated sharply (Q1 -7.6%, Q2 +10.9%, Q3 +38.6%), yet it is the only one of the four still down on the month apart from OCUL; the low P/S sits on top of a leveraged balance sheet (see Risks).

Move

Catalyst

Harrow reported Q3 2026 after the close on 11/9 (8-K press release and shareholder letter):

Coverage of the move credited the revenue beat and the return to profit; the intraday reversal suggests the market then weighed the EBITDA cut (inference).

Sector

Specialty ophthalmic pharma. This was a stock-specific move: on 11/10, XPH (pharma ETF) rose +0.8% and SPY fell -0.4%. Over the month XPH is +4.7%, XBI -0.1% and SPY -2.7%. HROW is -43.3% year to date against XPH +21.4%. Among eye-care peers, Tarsus is the growth leader (+63.9%, 93% gross margin) and Bausch + Lomb is the large, slow, profitable name.

Risks

Judgement

Overreaction (the gap), already mostly corrected. The revenue turn is real: growth went from -7.6% (Q1) to +10.9% (Q2) to +38.6% (Q3), VEVYE economics are improving with covered scripts, and a 10M-life plan starts in January. But a +20% gap priced only the top line. The same release cut profit guidance by half, leaned on a Q4 that must be the biggest in company history, and carried a warning that revenue could land below the guide. All of this comes on a balance sheet with ~$293M of 8.6% debt, $28.8M of equity and negative operating cash flow. The market corrected the move within the gap day itself (-8.2% from the open on 3.5x volume) and over the next two sessions. At +3% over the pre-report close, the price now roughly nets the real revenue gain against the halved profit outlook (inference). The next real test is the Q4 print.

Sources